Overall survival among patients with activated phosphoinositide 3-kinase delta syndrome (APDS)
Summary
Reduced survival in patients with APDS suggests a high disease burden, particularly in those with concurrent lymphoma. These results highlight the unmet need for disease-modifying treatments for APDS. © 2025. The Author(s).
| Authors | Mahendran M, Upton JEM, Ramasubramanian R, Memmott HL, Germain G, Büsch K, Laliberté F, Harrington A |
|---|---|
| Journal | Orphanet journal of rare diseases |
| Publication Date | 2025 May 3;20(1):212 |
| PubMed | 40319290 |
| PubMed Central | PMC12049806 |
| DOI | 10.1186/s13023-025-03734-z |